AU3295900A - Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist - Google Patents

Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist

Info

Publication number
AU3295900A
AU3295900A AU32959/00A AU3295900A AU3295900A AU 3295900 A AU3295900 A AU 3295900A AU 32959/00 A AU32959/00 A AU 32959/00A AU 3295900 A AU3295900 A AU 3295900A AU 3295900 A AU3295900 A AU 3295900A
Authority
AU
Australia
Prior art keywords
riluzole
combination
receptor antagonist
lateral sclerosis
ampa receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32959/00A
Other languages
English (en)
Inventor
Andrees Bohme
Alain Boireau
Thierry Canton
Jeremy Pratt
Jean-Marie Stutzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9903100A external-priority patent/FR2790670A1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of AU3295900A publication Critical patent/AU3295900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU32959/00A 1999-03-12 2000-03-10 Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist Abandoned AU3295900A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR9903100 1999-03-12
FR9903100A FR2790670A1 (fr) 1999-03-12 1999-03-12 Association riluzole et antagoniste des recepteurs ampa
US12931899P 1999-04-14 1999-04-14
US60129318 1999-04-14
PCT/FR2000/000590 WO2000054772A1 (fr) 1999-03-12 2000-03-10 Traitement de la sclerose laterale amyotrophique avec une association de riluzole et d'un antagoniste des recepteurs ampa

Publications (1)

Publication Number Publication Date
AU3295900A true AU3295900A (en) 2000-10-04

Family

ID=26234859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32959/00A Abandoned AU3295900A (en) 1999-03-12 2000-03-10 Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist

Country Status (4)

Country Link
EP (1) EP1161238A1 (fr)
JP (1) JP2002539162A (fr)
AU (1) AU3295900A (fr)
WO (1) WO2000054772A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009496A (es) * 2002-03-29 2005-01-25 Yamanouchi Pharma Co Ltd Remedio para glioblastoma.
US7045527B2 (en) 2002-09-24 2006-05-16 Amgen Inc. Piperidine derivatives
EP1798232A1 (fr) * 2005-12-08 2007-06-20 Hybrigenics S.A. Inhibiteurs de la cysteine protease, compositions pharmaceutiques et applications therapeutiques
WO2007066200A2 (fr) * 2005-12-08 2007-06-14 Hybrigenics Sa Inhibiteurs innovants des cysteine-proteases, leurs compositions pharmaceutiques et leurs applications therapeutiques
WO2010113225A1 (fr) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Timbre transdermique contenant du riluzole

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722789B1 (fr) * 1994-07-20 1996-08-23 Rhone Poulenc Rorer Sa Derives d'acide imidazo (1,2-a)indeno(1,2-e) pyrazine-2-carboxylique, leur preparation et les medicaments les contenant
US5780489A (en) * 1996-08-21 1998-07-14 Brooks; Benjamin Rix Method for treating amyotrophic lateral sclerosis
EP1011656A2 (fr) * 1996-11-05 2000-06-28 Head Explorer ApS Procede de traitement de cephalees du type par tension nerveuse
BR9906821A (pt) * 1998-01-09 2000-10-17 Mor Research Applic Ltd Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica

Also Published As

Publication number Publication date
EP1161238A1 (fr) 2001-12-12
JP2002539162A (ja) 2002-11-19
WO2000054772A1 (fr) 2000-09-21

Similar Documents

Publication Publication Date Title
AU2466099A (en) Pharmaceutically active compounds and methods of use thereof
AU4210599A (en) Electronic pillbox for administering a multiple-drug therapy
AU3042001A (en) Molded knee pad construction
AU4230900A (en) Purposeful movement of human migratory cells away from an agent source
AU2002341963A1 (en) Flushable commode liner
AU1927199A (en) Extensible absorbent article including a tearable layer
AU758325C (en) Imidazole compounds and medicinal use thereof
AU4345297A (en) Benzothiadiazide derivatives and their use as allosteric up-modulators of the ampa receptor
HK1076049A1 (en) Use of riluzole for treating multiple sclerosis
IL133136A0 (en) Use of leptin antagonists for the treatment of diabetes
AU1969800A (en) Combination of active agents
AU3295900A (en) Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
AU5957200A (en) Device for controlling the reflex response of muscles of a joint
AU6309999A (en) Therapeutic ankle orthosis
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
AU3760900A (en) Treatment of menstrual function
AU5696400A (en) Improved software interface agent
AU5531798A (en) Pharmacologically active compounds and use
HUP0104698A3 (en) Use of riluzole for treating acoustic traumas
AU2002307327A1 (en) Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
AU3071999A (en) Use of pkc inhibitors for the manufacture of a medicament for the treatment of autoimmune diseases
AU2462097A (en) The use of a substance p antagonist for the manufacture of medicament for the treatment of ocular pain
AU2002366793A1 (en) Improved lilly of the valley aromachemicals
AU1258699A (en) Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation
AU5461899A (en) Compatabilization of internal mold release agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase